Clinical Trial

ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

Study acronym: MOLTO
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a multicenter, open-label, uncontrolled, phase II trial aimed to establish the safety and tolerability of venetoclax, atezolizumab and obinutuzumab combination in Richter Transformation of CLL.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2019-09-05; most recent amendment 2024-05-24.
Status change: Recruiting → Active, Not Recruiting 2024-05-24
Status change: Not Yet Recruiting → Recruiting 2019-12-18
Trial Details
NCT Number NCT04082897
Lead Sponsor Niguarda Hospital
Conditions CLL Transformation
Enrollment 28 participants
Start Date 2019-10-04
Primary Completion 2026-09 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-05-28